- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07419425
Mon Chemin pour Arrêter le Tabac
Comparaison de trois interventions multicomposantes pour aider les adultes à arrêter de fumer
The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Primary Objective: Identify the most effective treatment for increasing long-term smoking abstinence among Black adults who smoke.
Secondary Objectives:
- Compare the 3 interventions on key patient-relevant outcomes (e.g., treatment satisfaction, smoke fewer cigarettes per day, quality of life) using validated measures collected at 8 and 26 weeks post-target quit day (TQD)
- Identify subgroups for whom these treatments are especially effective or ineffective with respect to the primary and secondary outcomes.
- Compare indices of treatment engagement (e.g., percentage of counseling sessions attended, percentage of days used nicotine patch) among Black people who smoke and are randomly assigned to the 3 different treatment conditions.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Megan Piper, PhD
- Numéro de téléphone: 608-265-5472
- E-mail: mep@ctri.wisc.edu
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85004
- Pas encore de recrutement
- Arizona State University
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Pas encore de recrutement
- Indiana University
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Pas encore de recrutement
- University of Kansas Medical Center Research Institute, Inc
-
-
Virginia
-
Richmond, Virginia, États-Unis, 23298
- Pas encore de recrutement
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53233
- Recrutement
- UW School of Medicine and Public Health
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- self-identify as Black
- smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days/week)
- motivated to quit smoking
- willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment.
Exclusion Criteria:
- currently taking bupropion for non-smoking cessation reasons
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard Intervention
The Standard Intervention will include 2 weeks of nicotine patches + 4 quitline-style counseling phone calls. |
Patch dosing will be consistent with the package insert
Autres noms:
4, 10 to 15-minute counseling sessions (the duration of a typical quitline call) will occur via phone one week prior to the TQD, 1 day after the TQD, and 1 and 2 weeks after the TQD. |
|
Expérimental: Intensive Intervention
The Intensive Intervention will include 8 weeks of nicotine patches (if eligible) + 8 counseling sessions (choice of individual phone or virtual group) + the Pathways to Freedom video content on the study website with additional smoking cessation content. |
Patch dosing will be consistent with the package insert
Autres noms:
Participants will have the option of choosing 8, 30-minute counseling phone calls or 8, 60-minute video group counseling sessions Pathways to Freedom video content, a 60-minute video that addresses key issues such as emotional dependence, nicotine replacement, identifying smoking triggers, developing coping skills, and other behavioral strategies people can use to support a quit attempt. |
|
Expérimental: Intensive Incentivized Intervention
The Intensive Incentivized Intervention will include all components provided in the Intensive intervention (8 weeks of nicotine patches (if eligible) + 8 counseling sessions (choice of individual phone or virtual group) + the Pathways to Freedom video content on the study website with additional smoking cessation content) and up to $50 for completing counseling sessions ($5 for completing sessions 1-6 and $10 for completing sessions 7 and 8) |
Patch dosing will be consistent with the package insert
Autres noms:
Participants will have the option of choosing 8, 30-minute counseling phone calls or 8, 60-minute video group counseling sessions Pathways to Freedom video content, a 60-minute video that addresses key issues such as emotional dependence, nicotine replacement, identifying smoking triggers, developing coping skills, and other behavioral strategies people can use to support a quit attempt. up to $50 for completing counseling sessions ($5 for completing sessions 1-6 and $10 for completing sessions 7 and 8) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day
Délai: 26 weeks post-TQD
|
The primary outcome for this study will be biochemically confirmed (anabasine less than 2 ng/ml) 7-day point-prevalence smoking abstinence at 26- weeks post-TQD |
26 weeks post-TQD
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Argent dépensé en cigarettes par semaine
Délai: à la ligne de base, 8 et 26 semaines après le TQD
|
à la ligne de base, 8 et 26 semaines après le TQD
|
|
|
Biochemically confirmed abstinence from any nicotine product at 26-weeks post-target quit day
Délai: 26 weeks post-TQD
|
salivary cotinine using a cut-off of less than 10 ng/ml to indicate abstinence from any nicotine product (combusted cigarettes, e-cigarettes, nicotine replacement therapy [NRT]) |
26 weeks post-TQD
|
|
Treatment Satisfaction
Délai: 8 weeks post-TQD
|
Scored from 1 to 7 where higher scores indicate increased satisfaction with treatment. |
8 weeks post-TQD
|
|
Cigarettes per day
Délai: baseline, 8 and 26 weeks post-TQD
|
Cigarettes per day based on the past 7 days. |
baseline, 8 and 26 weeks post-TQD
|
|
Quality of Life measured by the Medical Outcomes Study's 12-item Short Form Survey Instrument (SF-12)
Délai: baseline, 8 and 26 weeks post-TQD
|
Scores range from 0 to 100 where higher scores indicate better quality of life. |
baseline, 8 and 26 weeks post-TQD
|
|
Smoking Cessation Self-efficacy using a single 10-point Likert scale
Délai: baseline, 8 and 26 weeks post-TQD
|
Scores range from 1 to 10 where higher scores mean higher cessation self-efficacy. |
baseline, 8 and 26 weeks post-TQD
|
|
Psychological Distress measured by the 6-item Kessler screener (K6)
Délai: baseline, 8 and 26 weeks post-TQD
|
Total range of scores is from 0-24 where higher scores mean decreased psychological distress. |
baseline, 8 and 26 weeks post-TQD
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Megan Piper, PhD, UW School of Medicine and Public Health
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-1697
- SMPH / CTRI (Autre identifiant: UW Madison)
- BPS-2024C1-36762 (Autre subvention/numéro de financement: PCORI)
- Protocol Version 4/6/26 (Autre identifiant: UW Madison)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .